Compare Direxion Daily S&P 500 Bull 3X Shares (SPXL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion Daily S&P 500 Bull 3X Shares vs Vertex Pharmaceuticals Incorporated — how do they compare? Direxion Daily S&P 500 Bull 3X Shares trades at $298.52 (market cap $7.36B), while Vertex Pharmaceuticals Incorporated trades at $510.6 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 17.3× Direxion Daily S&P 500 Bull 3X Shares's market cap, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily S&P 500 Bull 3X Shares for 32 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SPXL | VRTX | |
|---|---|---|
Market Cap | $7.36B | $127.55B |
Volume | 1,835,467 | 1,487,944 |
Sector | Leveraged / Inverse | Health |
52-Week High | $301.38 | $557.96 |
52-Week Low | $170.20 | $407.37 |
Typical Hold Time | 32 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPXL trades at $298.10, up 0.42% with a bullish technical signal from moving averages. The ETF shows neutral momentum oscillators with RSI at 66.91 suggesting mild overbought conditions. Recent news highlights S&P 500 valuation concerns despite strong earnings growth projections of 35% for 2026. The index faces concentration risks with top holdings accounting for 40% of value.
Outlook remains cautiously optimistic with seasonal patterns favoring year-end rallies, though profit growth is expected to slow to 15% in 2027. Key risks include market concentration, geopolitical uncertainty, and potential Fed policy impacts. Technical support at $289 and resistance at $300 will be critical near-term levels.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
